Paper-Analytical Device for Saliva Biomarker Diagnostics

用于唾液生物标志物诊断的纸质分析装置

• 批准号: 10042909
• 负责人: Charles S Henry
• 金额: $ 37.13万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10042909
• 关键词: Address; Affect; Australia; Biological Assay; Biological Markers; Biosensor; Blood; Cardiovascular Diseases; Cessation of life; Clinical Research; Collaborations; Colorado; Cost Analysis; Detection; Development; Devices; Diagnostic; Diagnostic tests; Disease; Electrodes; Galectin 3; Head and Neck Cancer; Heart failure; Human; Immunoassay; International; Intervention; Laboratories; Link; Mainstreaming; Measurement; Measures; Methods; Morbidity - disease rate; Nitrites; Oral health; Paper; Point-of-Care Systems; Preparation; Process; Prognostic Marker; Proteins; Publications; Publishing; Queensland; Reagent; Reporting; Resources; Saliva; Sampling; Serum; Speed; System; Technology; Testing; Time; United States; Universities; Variant; Viscosity; Work; analytical method; base; cost; diagnostic assay; diagnostic biomarker; electric impedance; experience; improved; innovation; mortality; novel; novel strategies; pathogen; point of care; point-of-care diagnostics; portability; prognostic value; saliva analysis; sensor

Project Summary: Heart failure (HF) affects 5.7M people annually in the United States with 1 in 9 deaths linked to the disorder. Measuring diagnostic and prognostic biomarkers at the point of care is key for reducing HF-related deaths but invasive blood-based diagnostic tests require extensive resources and are expensive. A critical need for sensitive assays that utilize non-invasive samples remains a pressing need for point-of-care diagnostics. Here, we propose to develop an innovative solution to rapid, sensitive, and inexpensive measurements of biomarkers in saliva that are correlated with HF. To address this need, a paper-based analytic device (PAD) that combines saliva sample processing with sensitive electrochemical biosensors to detect galectin-3 (Gal-3) and s100A7 as biomarkers of HF in saliva will be developed. The project consists of two aims, 1) demonstration of a sensitive, selective electrochemical PAD for s100A7 and Gal-3 and 2) development of a PAD that can rapidly and efficiently process saliva of varying viscosities in minutes. This project is an international collaboration between the Henry group at Colorado State University (CSU) and the Punyadeera group at the Queensland University of Technology (QUT) in Australia. The international collaboration is justified because the Henry group has expertise in PADs and the Punyadeera group has experience with saliva-based diagnostics. Once successful, we will expand both the number and type of biomarkers for both cardiovascular disease and head/neck cancers. We will also be poised to expand on-going clinical studies of saliva-based biomarkers to further validate their use as non-invasive biomarkers.

项目概要： 在美国，心力衰竭 (HF) 每年影响 570 万人，其中九分之一的死亡与该疾病有关。 在护理点测量诊断和预后生物标志物是减少心力衰竭相关死亡的关键，但 基于血液的侵入性诊断测试需要大量资源并且价格昂贵。对敏感的迫切需求 利用非侵入性样本的检测仍然是即时诊断的迫切需求。在此，我们建议 开发一种创新的解决方案，快速、灵敏且廉价地测量唾液中的生物标志物 与 HF 相关。为了满足这一需求，结合了唾液样本的纸质分析装置 (PAD) 使用灵敏的电化学生物传感器进行处理，检测半乳糖凝集素 3 (Gal-3) 和 s100A7 作为生物标志物 唾液中会产生HF。该项目有两个目标，1）展示敏感的、有选择性的 用于 s100A7 和 Gal-3 的电化学 PAD 以及 2) 开发能够快速高效处理的 PAD 在几分钟内产生不同粘度的唾液。该项目是亨利集团之间的国际合作 科罗拉多州立大学 (CSU) 和昆士兰科技大学 (QUT) 的 Punyadeera 小组 在澳大利亚。国际合作是合理的，因为亨利集团在 PAD 和 Punyadeera 小组在基于唾液的诊断方面拥有丰富的经验。一旦成功，我们将扩大双方的数量 以及心血管疾病和头颈癌的生物标志物类型。我们也将准备扩大 正在进行的基于唾液的生物标志物的临床研究，以进一步验证其作为非侵入性生物标志物的用途。